当前位置: 首页 >> 检索结果
1. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
作者: Walter P Maksymowych.;Robert G W Lambert.;Rebecca J Bolce.;Natalia Bello.;Baojin Zhu.;Jeffrey R Lisse.;Mikkel Østergaard.
来源: Lancet Rheumatol. 2025年7卷5期e314-e322页
The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study.
2. Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial.
作者: Michelle Hall.;Kim Allison.;Gabrielle Knox.;Fiona McManus.;Rana S Hinman.;Kim L Bennell.;Libby Spiers.;Anurika P De Silva.;David M Klyne.;Melanie L Plinsinga.;Ricardo J S Costa.;Nicholas J Murphy.;Wen Wu.;Fiona L Dobson.
来源: Lancet Rheumatol. 2025年7卷5期e343-e354页
Exercise is recommended for hip osteoarthritis, but the most effective programmes for management of symptoms are unknown. We aimed to investigate whether adding aerobic physical activity to resistance exercise would improve hip pain and function more than resistance exercise alone in individuals with hip osteoarthritis.
3. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial.
作者: Håvard Fretheim.;Imon Barua.;Gunnstein Bakland.;Alvilde Dhainaut.;Anne-Kristine Halse.;Maylen N Carstens.;Henriette Didriksen.;Øyvind Midtvedt.;Knut E A Lundin.;Lars Aabakken.;Vikas K Sarna.;Hasse K Zaré.;Dinesh Khanna.;Oliver Distler.;Tore Midtvedt.;Espen S Bækkevold.;Inge C Olsen.;Diana Domanska.;Maiju E Pesonen.;Øyvind Molberg.;Anna-Maria Hoffmann-Vold.
来源: Lancet Rheumatol. 2025年7卷5期e323-e332页
Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal microbiome (ACHIM) as a novel treatment option for patients with systemic sclerosis and symptomatic lower gastrointestinal tract involvement.
4. Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial.
作者: Alain Saraux.;Guillermo Carvajal Alegria.;Emmanuelle Dernis.;Christian Roux.;Christophe Richez.;Alice Tison.;Baptiste Quere.;Sandrine Jousse-Joulin.;Dewi Guellec.;Thierry Marhadour.;Patrice Kervarrec.;Divi Cornec.;Catherine Le Henaff.;Sandra Lesven.;Emmanuel Nowak.;Aghiles Souki.;Valérie Devauchelle-Pensec.
来源: Lancet Rheumatol. 2025年7卷4期e233-e242页
Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use of oral glucocorticoids in people with recent-onset polymyalgia rheumatica.
5. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.
作者: Hans-Joachim Anders.;Tak Mao Chan.;Jorge Sanchez-Guerrero.;David Wofsy.;Karen Bensley.;Lilianne Kim.;Kim Hung Lo.;Cathye Shu.;Jie Shao.;Chetan S Karyekar.;Betty Diamond.
来源: Rheumatology (Oxford). 2025年64卷5期2731-2740页
Evaluate the efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in a phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active LN.
6. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
作者: Anca D Askanase.;David D'Cruz.;Kenneth Kalunian.;Joan T Merrill.;Sandra V Navarra.;Clélia Cahuzac.;Peter Cornelisse.;Mark J Murphy.;Daniel S Strasser.;Luba Trokan.;Ouali Berkani.
来源: Lancet Rheumatol. 2025年7卷1期e21-e32页
Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). We aimed to determine the efficacy, safety, and tolerability of four doses of cenerimod in adults with moderate-to-severe SLE receiving standard of care background therapy.
7. A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial.
作者: Michaël Doumen.;Elias De Meyst.;Delphine Bertrand.;Sofia Pazmino.;Marine Piessens.;Johan Joly.;Mieke Devinck.;René Westhovens.;Patrick Verschueren.
来源: Rheumatology (Oxford). 2025年64卷5期2505-2514页
The aim of this work was to determine whether smartphone applications could support the self-management of RA and to investigate engagement and potential negative psychological effects with app-use.
8. Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort.
作者: Yann Nguyen.;Gabriel Baron.;Naima Hamamouche.;Rakiba Belkhir.;Sylvie Miconnet.;Martin Soubrier.;Camille Hostachy.;Pascale Thevenot.;André Basch.;Marie-Elise Truchetet.;Pascal Claudepierre.;Emmanuelle Dernis.;Hubert Marotte.;René-Marc Flipo.;Olivier Brocq.;Jacques Morel.;Bruno Fautrel.;Carine Salliot.;Alain Saraux.;Charles Leske.;Thierry Schaeverbeke.;Philippe Ravaud.;Xavier Mariette.;Adeline Ruyssen-Witrand.;Raphaèle Seror.; .
来源: Rheumatology (Oxford). 2025年64卷5期2496-2504页
The objectives of this study were to evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among RA patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
9. Patient-initiated follow-up supported by asynchronous telemedicine versus usual care in spondyloarthritis (TeleSpA-study): a randomised controlled trial of clinical and cost-effectiveness.
作者: Kasper Hermans.;Casper Webers.;Annelies Boonen.;Harald E Vonkeman.;Astrid van Tubergen.
来源: Lancet Rheumatol. 2024年6卷12期e848-e859页
With rising health-care expenditures and workforce shortages, sustainable alternatives to traditional outpatient follow-up strategies are required to optimise care efficiency. We aimed to investigate the cost-effectiveness and clinical effectiveness of patient-initiated follow-up (PIFU) supported by asynchronous telemedicine for patients with spondyloarthritis compared with usual care in daily practice.
10. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
作者: Hong Zhang.;Qianqian Li.;Cuiyun Li.;Min Wu.;Hong Chen.;Yang Li.;Feng You.;Yanshi Zhao.;Jing Jin.;Xiaoguang Chen.;Yanhua Ding.
来源: Lancet Rheumatol. 2024年6卷12期e837-e847页
Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for rheumatoid arthritis. We aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of proximod in healthy volunteers and patients with rheumatoid arthritis.
11. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.
作者: Laure Gossec.;Xenofon Baraliakos.;Daniel Aletaha.;Mohamed Sharaf.;Emmanouil Rampakakis.;Frédéric Lavie.;Clementina López-Medina.;Carlo Selmi.;Laura C Coates.
来源: Rheumatology (Oxford). 2025年64卷5期2565-2574页
Evaluate guselkumab efficacy, an anti-interleukin-23p19-subunit antibody, in patients with active psoriatic arthritis (PsA) and inadequate response to 1 or 2 tumour necrosis factor inhibitors (TNFi-IR), utilizing composite indices assessing disease activity across disease domains.
12. Infliximab vs interferon-α in the treatment of Behçet's syndrome: clinical data from the BIO-BEHÇET'S randomized controlled trial.
作者: Robert J Moots.;Farida Fortune.;Richard Jackson.;Tony Thornburn.;Ann Morgan.;Daniel F Carr.;Philip I Murray.;Graham R Wallace.;Deva Situnayake.
来源: Rheumatology (Oxford). 2025年64卷5期2882-2891页
Whilst biologic therapy is used for Behçet's syndrome of all subtypes refractory to first-line immunomodulation, there has been an absence of high-quality evidence and no predictive biomarkers to optimally inform choice. BIO-BEHÇET'S was a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet's.
13. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.
作者: Arthur Kavanaugh.;Laura C Coates.;Philip J Mease.;Miroslawa Nowak.;Lauren Hippeli.;Thomas Lehman.;Subhashis Banerjee.;Joseph F Merola.
来源: Rheumatology (Oxford). 2025年64卷5期2557-2564页
Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious than placebo across multiple endpoints, including achieving minimal disease activity (MDA). This post hoc analysis further evaluated the achievement of individual components of the MDA criteria with deucravacitinib treatment and the time course of responses in the phase 2 trial.
14. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial.
作者: Amanda Malone.;Mark M Kowalski.;James Helliwell.;Sidsel Lynggaard Boll.;Helene Rovsing.;Kathrine Moriat.;Alejandro Castillo Mondragón.;Yanqi Li.;Claire Prener Miller.;Asger Reinstrup Bihlet.;Christine Dobek.;Vik Peck.;Mike Wilmink.;Lee S Simon.;Philip G Conaghan.
来源: Lancet Rheumatol. 2024年6卷12期e860-e870页
Corticosteroids are among the few effective treatments for knee osteoarthritis, but short duration of action limits their utility. EP-104IAR, a long-acting formulation of fluticasone propionate for intra-articular injection, optimises the action of fluticasone propionate through novel diffusion-based extended-release technology. The SPRINGBOARD trial assessed the efficacy, safety, and pharmacokinetics of EP-104IAR in people with knee osteoarthritis.
15. Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.
作者: Maya H Buch.;David Walker.;Christopher J Edwards.;Jane Barry.;Laura Akroyd.;Edmund V Ekoka Omoruyi.;Peter C Taylor.
来源: Rheumatology (Oxford). 2025年64卷4期1661-1671页
Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis assessed the efficacy and safety of filgotinib in moderately active RA.
16. Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial.
作者: Quirine A Dumoulin.;Doortje I Krijbolder.;Karen Visser.;Leroy R Lard.;Annette H M van der Helm-van Mil.
来源: Lancet Rheumatol. 2024年6卷12期e827-e836页
Prevention of rheumatoid arthritis has become a definitive target. However, whether prevention of anti-citrullinated protein antibody (ACPA)-negative rheumatoid arthritis is possible is still unknown. We aimed to assess the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis.
17. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial.
作者: Zhenyu Zhong.;Dan Deng.;Yu Gao.;Qingqing Bu.;Lingyu Dai.;Xiaojie Feng.;Chong Tang.;Xiang Luo.;Yao Wang.;Chunjiang Zhou.;Guannan Su.;Peizeng Yang.
来源: Lancet Rheumatol. 2024年6卷11期e780-e790页
Data from head-to-head trials of immunomodulatory therapies for Behçet's disease are scarce. We aimed to compare the efficacy and safety of ciclosporin, interferon alfa-2a, and adalimumab, each combined with corticosteroids, in preventing uveitis relapse in patients with severe Behçet's disease.
18. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.
作者: Josef S Smolen.;Peter C Taylor.;Yoshiya Tanaka.;Tsutomu Takeuchi.;Motomu Hashimoto.;Carlos Cara.;Bernard Lauwerys.;Nicola Tilt.;Baran Ufuktepe.;Ricardo M Xavier.;Alejandro Balsa.;Jeffrey R Curtis.;Ted R Mikuls.;Michael Weinblatt.
来源: Rheumatology (Oxford). 2024年63卷11期3015-3024页
To assess the impact of baseline RF level on drug concentrations and efficacy of certolizumab pegol [CZP; TNF inhibitor (TNFi) without a crystallizable fragment (Fc)] and adalimumab (ADA; Fc-containing TNFi) in patients with RA.
19. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
作者: Ioannis Parodis.;Julius Lindblom.;Roger A Levy.;Margherita Zen.;Nursen Cetrez.;Alvaro Gomez.;Shereen Oon.;Christine Henning.;Munther Khamashta.;Holly A Quasny.;Deven Chauhan.;Anca Askanase.;Ronald van Vollenhoven.;Mandana Nikpour.
来源: Lancet Rheumatol. 2024年6卷11期e751-e761页
Disease remission or low disease activity are key treatment targets for patients with systemic lupus erythematosus (SLE). Pivotal trials of belimumab were conducted before the introduction of these targets. In this study, we aimed to pool data across trials to assess attainment of remission and low disease activity in a large, racially and culturally diverse patient population with SLE.
20. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
作者: Atul Deodhar.;Alan J Kivitz.;Marina Magrey.;Jessica A Walsh.;Philip J Mease.;Maria Greenwald.;Farid Kianifard.;Chelsea Elam.;Gopi M Bommidi.;Adam Winseck.;Lianne S Gensler.
来源: Rheumatology (Oxford). 2025年64卷4期1864-1872页
To investigate the clinical response at week 52 in patients with AS who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week 16.
|